NVS - Forty Seven Validates CD47 With 'Don't Eat Me' Tech Pivotal Studies To Be Initiated In 2020
Forty Seven Inc. (FTSV) had achieved positive results from an early-stage study in treatment-naive patients with high-risk myelodysplastic syndrome ((MDS)) and acute myeloid leukemia ((AML)). The positive results were obtained using the company's drug magrolimab in combination with Vidaza (also known as Azacitidine). The importance of these results comes on the basis that a large majority of patients with high-risk MDS don't have an available treatment option suited to help treat their disease. It is expected that a phase 3 trial, known as ENHANCE, will be initiated in Q2 of 2020. Additional results from the